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Abstract: Glucagon-like peptide-1 (GLP-1) receptor agonists have been available as glu-
cose-lowering therapies for people with type 2 diabetes since 2006, when twice-daily
exenatide was licenced. Since then, advances in peptide chemistry and delivery have allowed
for once-daily and more recently once-weekly (QW) delivery of peptides in this class and
there are currently three QW “long-acting” GLP-1 receptor agonists available in clinical
practice. This short review describes the therapeutic landscape that is occupied by the
modern type 2 diabetes glucose-lowering therapies with a particular focus on long-acting
GLP-1 receptor agonists. The efﬁcacy and side-effect proﬁles of the available QW GLP-1
receptor agonists are discussed, focusing on head-to-head clinical trial comparisons. There is
also an appraisal of the cardiovascular outcome trials, for which there has been an assess-
ment of each of the QW GLP-1 receptor agonists, leading to clinical conclusions regarding
their comparative effectiveness.
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Introduction
The incidence of type 2 diabetes mellitus (T2D) continues to rise and it is estimated
that 9% of the global adult population are affected by this condition. In the United
Kingdom, 10% of healthcare spend is attributable to diabetes and in the most recent
audit of National Health Service hospitals, 20% of in-patients have diabetes as a co-
morbidity. Attempts to reduce the burden of the “diabetes epidemic” by prevention
have been universally unsuccessful, due to failure to reverse rising levels of obesity
and sedentary lifestyle. This has led to a proliferation of pharmacologic therapies
for hyperglycaemia and in the United States, there are now ten different classes of
glucose-lowering medication.
Two of these drug classes, initially launched in the mid-2000s, impact on the
incretin system. They stimulate the glucagon-like peptide 1 (GLP-1) receptor,
which enhances insulin secretion and reduces the production of glucagon, both in
a glucose-dependent manner. The dipeptidyl peptase-4 (DPP-4) inhibitors are oral
agents, which enhance endogenous GLP-1 activity by reducing its degradation by
the widely distributed enzyme DPP-4. Their mechanism of action means that they
do not cause hypoglycaemia nor lead to weight gain. They have also been shown to
be safe in large studies examining their potential to increase cardiovascular (CV)
disease (a mandatory regulatory requirement for new glucose-lowering therapies).
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The second class of incretin agents are the GLP-1
receptor agonists (GLP-1RAs). These are injectable pep-
tides which are resistant to DPP-4 degradation, providing
supra-physiological stimulation of the GLP-1 receptor.
GLP-1RAs also slow gastric emptying and, probably via
an effect on the brain, increase satiety; both of these
effects lead to weight loss in a substantial proportion of
patients. They are, however, less well tolerated than DPP-4
inhibitors, with gastro-intestinal side-effects of nausea,
vomiting and diarrhoea being common following initiation
(although these diminish over time in most subjects).
The ﬁrst GLP-1RA to be marketed (exenatide [Byetta®])
was based on the exendin-4 molecule (isolated from the
saliva of the Gila Monster lizard) and had to be administered
twice daily with meals due to its short half-life.1
Subsequently launched GLP-1RAs were once-daily prepara-
tions (liraglutide [Victoza®] and lixisenatide [Lyxumia®])
which could be administered without regard to meal
times;2,3 in 2011 the European Medicines Agency issued
marketing authorisation for a once-weekly (QW) version of
exenatide [Bydureon®], the ﬁrst long-acting GLP-1RA.4
Exenatide extended release (ER) contains the exendin-
4 molecule interlinked with microspheres of poly-(D,
L-lactide-co-glycolide) polymers, degradable material
that had previously been used in absorbable sutures. The
absorption of exenatide involves an initial phase of release
for 48 hrs, then continued diffusion of exenatide for four-
teen days; ﬁnally, there is release mediated by erosion for
up to seven weeks. These pharmacokinetic features facil-
itate a continual release of drug without signiﬁcant peaks
and troughs in plasma concentration and allow for once
weekly (QW) administration. Exenatide ER is prescribed
as a powder and this needs to be suspended in aqueous
solution immediately prior to injection; this has led to the
development of various devices to aid suspension, some of
which have involved vigorous shaking. There is also an
issue of injection-site swelling due to the slow clearance of
polymer, which can still be felt four weeks post-injection.
Exenatide ER is administered as a single dose of 2mg QW
with no need for slow up-titration.
The second long-acting GLP-1RA launched in 2014
was albiglutide (Eperzan®), closely followed by dulaglu-
tide (Trulicity®).5,6 Unlike exenatide, both of these GLP-
1RAs are analogues of the human GLP-1 molecule rather
than exendin-4. Albiglutide is made up of multiple copies
of a modiﬁed human glucagon-like peptide (amino acids
7–36) coupled to recombinant human albumin. After sub-
cutaneous administration it appears to be absorbed via the
lymphatic circulation with a maximum plasma concentra-
tion achieved around four days and with steady state after
4–5 weeks QW administration. Unfortunately, the admin-
istration of this medication is also complicated involving
two periods of mixing separated by a 15–30 min wait,
depending on the dose (30–50mg).
Dulaglutide is a recombinant DNA-produced polypep-
tide analogue of human GLP-1 (amino acids 7–37) which
is covalently linked to each Fc arm of human immunoglo-
bulin G4 (IgG4). This structure improves solubility and
reduces immunogenicity, whilst also lowering renal clear-
ance. As a result of the solubility, no shaking or mixing is
required and the administration is very simple. Dulaglutide
is administered in two doses (0.75mg and 1.5mg QW)
without the need for up-titration.
The most recently lunched long-acting GLP-1RA (2018)
is semaglutide (Ozempic®).7 This molecule differs from
human GLP-1 by two amino acids (94% homology), one of
which protects against DPP4 degradation. There is an 18
carbon fatty diacid chain attached via a spacer to the lysine
amino acid at position 26 of the molecule, which provides
strong binding to albumin, facilitating the prolongation of
action. Semaglutide is delivered as a clear, colourless solution
which does not require resuspension. It is initiated at a dose of
0.25mg QW titrated after one month to a maintenance dose of
0.5mg or, with further up-titration, 1.0mg QW.
As mentioned earlier, all new glucose-lowering thera-
pies are subjected to cardiovascular outcome trials
(CVOTs) and, as per the FDA mandate, the long-acting
GLP-1RAs have been assessed against placebo. The
CVOT for exenatide ER conﬁrmed non-inferiority (i.e.
cardiovascular safety) but did not show superiority for
the primary end-point, which was a composite of major
cardiovascular events (CV death, non-fatal myocardial
infarction or non-fatal stroke, termed 3-P MACE).8 In
contrast, the long-acting GLP-1 analogues (albiglutide,
dulaglutide & semaglutide) have not only been found to
be safe but have also demonstrated CV beneﬁt over
placebo.9–11 It is quite possible that this represents dif-
ferences in the trial designs and, indeed, meta-analyses
suggest no signiﬁcant differences between medications
in this class.12 However, the CVOT of lixisenatide,
which is also exendin-4 based did not show CV super-
iority whilst the LEADER trial of liraglutide, a molecule
closely analogous to semaglutide was positive.13,14
Unlike most classes of glucose-lowering therapies, some
head-to-head comparisons of long-acting GLP-1RAs have
been published, allowing some direct comparison of
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effectiveness. The SUSTAIN 3 trial compared the safety
and efﬁcacy of semaglutide 1.0mg QW with exenatide ER
2.0mg QW in a Phase 3a, open-label, randomised clinical
trial.15 813 subjects with T2D already taking oral glucose-
lowering medications were randomised to active compara-
tor therapy for 56 weeks with the primary end-point being
change from baseline HbA1c.
The mean HbA1c (baseline 8.3% [67.7 mmol/mol])
fell by 1.5% (16.8mmol/mol) in subjects receiving sema-
glutide and by 0.9% (10.0 mmol/mol) with exenatide ER
(estimated treatment difference [ETD] −0.62% [95% CI
−0.80, −0.44] [−6.78 mmol/mol (95% CI −8.70, −4.86)]).
This was statistically signiﬁcant for both non-inferiority
and superiority, in favour of semaglutide, and more
patients receiving semaglutide (67%) achieved an HbA1c
<7.0% (<53 mmol/mol) versus 40% of those taking exena-
tide ER. The baseline bodyweight (mean of 95.8 kg) was
lowered by 5.6 kg (semaglutide) and 1.9 kg (exenatide
ER) respectively, giving an ETD −3.78 kg [95% CI
−4.58, −2.98] which was highly signiﬁcant. The treatments
both had similar safety proﬁles although gastrointestinal
adverse events were more common with semaglutide
(41.8%) than with exenatide ER (33.3%). Injection-site
reactions were more frequently reported with exenatide
ER (22.0%) than with semaglutide (1.2%).
The SUSTAIN 7 trial compared once-weekly semaglu-
tide with dulaglutide in people with sub-optimally con-
trolled T2D.16 This open-label, parallel-group, phase 3b
trial recruited patients aged 18 years or older who were on
metformin monotherapy with an HbA1c between 7.0–
10.5% (53.0–91.0 mmol/mol). Patients were randomised
to receive semaglutide 0.5 mg QW, dulaglutide 0.75 mg
QW, semaglutide 1.0 mg QW or dulaglutide 1.5 mg QW.
The primary endpoint of SUSTAIN 7 was change in HbA1c
from baseline; a secondary endpoint considered the change
in bodyweight after 40 weeks treatment exposure. The trial
was powered for HbA1c non-inferiority (set at a margin of
0.4%, [4.4mmol/mol]) and for bodyweight superiority.
A total of 1201 patients were randomised with similar
numbers of participants (~300) in each of the four study arms
and approximately 6% of patients withdrew from the study
(43 receiving semaglutide and 29 receiving dulaglutide). The
mean HbA1c was reduced by 1.5% (16.4 mmol/mol) with
0.5 mg semaglutide compared with 1.1% (12.1mmol/mol)
with 0.75mg dulaglutide and this difference was statistically
signiﬁcant, in favour of semaglutide. Similarly, comparison
of the higher doses of the two agents showed a signiﬁcantly
better reduction in HbA1c for semaglutide (ETD −0.41%
[4.5mmol/mol]; p<0.0001). For the secondary end-point of
bodyweight, this was reduced by 4.6–6.5 Kg for the two
doses of semaglutide compared with 2.3–3.0 Kg with dula-
glutide; comparisons of the respective doses were highly
signiﬁcant, both favouring semaglutide.
As expected, gastrointestinal adverse events were fre-
quently reported and occurred in, 43–44% of subjects receiv-
ing semaglutide compared with 33–48% with the two doses
of dulaglutide. These side-effects were also the most com-
mon reason for discontinuing treatment in the trial.
Albiglutide has not been directly compared with either
semaglutide or dulaglutide but was assessed versus once-
daily liraglutide in the HARMONY 7 trial.17 Comparison
with liraglutide is of interest since this agent was also in
a head-to-head comparison with once-weekly exenatide ER
in the DURATION-6 trial, where liraglutide was seen to be
superior to exenatide ER in terms of HbA1c lowering.18
HARMONY 7 was a 32-week, open-label, phase 3 trial
which recruited 841 adults with suboptimally controlled
T2D and BMI 20–45 kg/m2. Subjects were randomised to
receive albiglutide 30 mg QW titrated to 50 mg at week 6, or
liraglutide titrated to 1.8 mg OD over a two week period.17
The primary endpoint was change in HbA1c from baseline
for both albiglutide versus liraglutide, with a 95% CI upper
margin of 0.3% to show non-inferiority. 422 subjects were
allocated to the albiglutide group and 419 to liraglutide and
the change in HbA1c at week 32 was −0.78% (8.6mmol/mol)
in the albiglutide group and −0.99% (10.9mmol/mol) in the
liraglutide group. The treatment difference was 0.21% with
conﬁdence intervals (0.08–0.34%) extending beyond 0.3%
and so non-inferiority was not demonstrated, i.e. liraglutide
showed superior glucose lowering to albiglutide. More
patients given albiglutide experienced injection-site reactions
compared to subjects who received liraglutide (12.9% vs
5.4%), whereas the opposite was seen for gastrointestinal
adverse events, which occurred in 49.0% of patients in the
liraglutide group versus 35.9% in the albiglutide group; both
of these between-group differences were statistically
signiﬁcant.
The similar levels of difference in HbA1c reduction for
both exenatide ER (DURATION-6) and albiglutide
(HARMONY 7) compared to liraglutide are consistent with
an indirect comparison of the two studies using a Bucher
analysis.19 This showed a treatment difference of 0.0% in
mean change in HbA1c from baseline, and that albiglutide
50 mg was non-inferior to exenatide 2.0 mg QWat the non-
inferiority margin of 0.3%. The effect of different agents on
Dovepress Chudleigh et al
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HbA1c and body weight in the various studies reported here
are summarised in Table 1.
Current licencing for GLP 1RAs recommends their use
to improve glycaemic control alongside other glucose-
lowering medications including insulin. The 2018 joint
ADA/EASD guidelines for the management of hypergly-
caemia in patients with type 2 diabetes promote the use of
GLP 1 RAs or SGLT2i as second-line therapy in those
with Atherosclerotic cardiovascular disease (ASCVD),
heart failure or renal impairment.20 The decision on
which agent to recommend will largely be dictated by
individual factors such as co-morbidity and renal function.
However, there is interest in the use of GLP 1 RAs and
SGLT2i in combination. Although evidence is scarce on
the use of this combination, The DURATION 8 study
demonstrated that the combination of Exenatide ER and
Dapagliﬂozin resulted in greater improvements in glycae-
mic control, weight and systolic blood pressure than when
either drug used alone.21 Similarly, the addition of
Dulaglutide in patients already treated with SGLT2i and
uncontrolled Diabetes produced additional reductions in
HbA1c and greater weight loss versus placebo.22 It is
speculated than the addition of a GLP 1 RA may reduce
the higher glucagon levels seen with SGLT2i therapy.
Conclusions
In terms of HbA1c and weight, it appears that semaglutide
is the most efﬁcacious of the currently available long-
acting GLP-1RAs. Regarding side-effects, which are pre-
dominantly gastro-intestinal, these appear to be a class
effect but with some relationship to glucose-lowering
potency (more with semaglutide, less with albiglutide).
Increased diabetic retinopathy (DR) events seen with
semaglutide in SUSTAIN 6 are thought to be related to
rapid reduction in glucose levels in subjects with poor
glycaemic control and existing retinopathy.11,23,24 It is of
note that a non-signiﬁcant increase in DR events was also
seen in the CVOTs for both liraglutide and dulaglutide10,14
consistent with an impact of potent glucose-lowering.
Other aspects will also impact on clinical decision-
making, for example, the injection preparation (proble-
matic for exenatide ER and albiglutide) as well as the
design of administration device, which may favour dula-
glutide. These tend to be reﬂected in quality of life
assessments.25 Finally, there is the issue of cost, which
will obviously vary in different health care systems. Where
the prices of the long-acting GLP-1RAs are equivalent,
then health technology analyses are largely driven by
HbA1c and weight and reﬂect differences in efﬁcacy.26
End note
Albiglutide was globally withdrawn for commercial rea-
sons in July 2018. However, the CVOT for albiglutide was
subsequently published and demonstrated superiority and
so it has been suggested that another pharmaceutical com-
pany may relaunch this product in the future and so it has
been included in this review.
Disclosure
Dr Richard A Chudleigh reports personal fees from Novo
Nordisk, Eli Lilly, Merck Sharpe & Dohme, Boehringer
Ingelheim, Astra Zeneca, Takeda, Napp., outside the sub-
mitted work. Professor Stephen Bain reports grants, perso-
nal fees, travel support to and registration at medical
Table 1 Effect of Treatment on HbA1c and Body Weight
Study Drug Dose Frequency HbA1c ReductionMean (SE) BodyWeight Change Mean (SE/SD)
SUSTAIN 315 Exenatide ER 2 mg Weekly −0.9 (0.06) % −1.9 (0.29) kg
Semaglutide 1 mg Weekly −1.5 (0.06) % −5.6 (0.29) kg
SUSTAIN 7 (low dose)16 Dulaglutide 0.75 mg Weekly −1.1 (0.05) % −2.3 (0.27) kg
Semaglutide 0.5 mg Weekly −1.5 (0.06) % −4.6 (0.28) kg
SUSTAIN 7 (high dose)16 Dulaglutide 1.5 mg Weekly −1.4 (0.06) % −3.0 (0.27) kg
Semaglutide 1.0 mg Weekly −1.8 (0.06) % −6.5 (0.28) kg
HARMONY 717 Albiglutide 50 mg Weekly −0.78% −0.6 (3.12) kg
Liraglutide 1.8 mg Daily −0.98% −2.2 (4.15) kg
DURATION 618 Exenatide ER 2 mg Weekly −1.28 (0.05) % −2.68 (0.18) kg
Liraglutide 1.8 mg Daily −1.48% (0.05) % −3.57 (0.18) kg
Note: Results in bold type represent signiﬁcant beneﬁt (p < 0.05) in outcome over the comparator drug.
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meetings from Novo Nordisk, Eli Lilly, Sanoﬁ, and Astra
Zeneca, outside the submitted work; and Professor Bain has
given expert advice on this class of glucose-lowering agents
to the National Institute for Health and Care Excellence
(NICE) and the All-Wales Medicines Strategy Group. The
authors report no other conﬂicts of interest in this work.
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